Metabolic dysfunction-associated steatotic liver disease (MASLD) closely associates with
obesity and type 2 diabetes. Lifestyle intervention and bariatric surgery aiming at substantial …

Non-alcoholic fatty liver disease (NAFLD) is a common comorbidity in individuals with
obesity. Although multiple pharmacotherapeutics are in development, currently there are …

Background The current obesity pandemic has given rise to associated comorbidities and
complications, including type 2 diabetes and metabolic dysfunction‐associated steatotic …

Metabolic dysfunction-associated steatotic liver disease (MASLD) affects one in three to four
adult individuals and can progress to metabolic dysfunction-associated steatohepatitis …

Metabolic dysfunction-associated fatty liver disease (MAFLD) is a chronic condition that
affects nearly one billion people globally, characterized by triacylglycerol accumulation in …

Metabolic-dysfunction associated steatotic liver disease (MASLD) affects 1 out of every 3
individuals in the adult population and the disease prevalence is predicted to increase …

Over the past decade, there have been several guideline updates for the diagnosis and
management of non-alcoholic fatty liver disease (NAFLD), which is the most common …

Metabolic dysfunction-associated steatotic liver disease (MASLD), previously termed non-
alcoholic fatty liver disease (NAFLD), is defined as steatotic liver disease (SLD) in the …

Lanifibranor, a pan-PPAR agonist, improves liver histology in patients with metabolic
dysfunction-associated steatohepatitis (MASH), who have poor cardiometabolic health …

Metabolic dysfunction-associated steatotic liver disease (MASLD) affects more than 30% of
the world's adult population. While it is associated with obesity and metabolic syndrome …